The Propriety of Sponsorship of Dermatologic Conferences

Ortonne, Jean-Paul; Camacho‐Martínez, F.; Freedman, Derek; Katsambas, Andreas; Powell, Frank C.; Roseeuw, Diane; Lotti, Torello; Vloten, Willem van

doi:10.1001/archderm.136.3.308

Cited by 3 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ascorbic acid and its derivatives are easily oxidized. Hydroquinone has a good whiting effect but its application is restricted due to allergic reactions and melanocyte-toxicity [11]. Thus, applications of these compounds are restricted in the cosmeceutical industry.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of melanogenesis by Erigeron canadensis via down-regulating melanogenic enzymes in B16F10 melanoma cells

Hong

Nguyen

et al. 2008

Korean J. Chem. Eng.

View full text Add to dashboard Cite

The effects of Erigeron canadensis extract on melanogenesis and cell toxicity in cultured B16F10 mouse melanoma cells were investigated. E. canadensis extract down regulated melanin synthesis effectively at a non-toxic concentration. Its extract was fractionated by using a recycling HPLC with GS310 column (21.5×500 mm, 10-15 μM) into five fractions. The fraction 1 showed melanin inhibition by 48.0% at 100 mg/ml which was 2.5 times more efficient than the depigmenting effect of commercial arbutin (17.5%) and also did not show cell toxicity. To elucidate the depigmenting mechanism of fraction 1, in vitro and cellular tyrosinase activity, antioxidant activity, and protein level of the main melanogenic enzymes, such as tyrosinase, TRP-1 and TRP-2 were evaluated. Fraction 1 inhibited melanin synthesis in B16F10 melanoma cells by decreasing protein levels of melanogenic enzymes, especially tyrosinase. In conclusion, we suggest that this fraction may be a safe and effective depigmentation agent.

show abstract

Section: Introductionmentioning

confidence: 99%

Inhibition of melanogenesis by Erigeron canadensis via down-regulating melanogenic enzymes in B16F10 melanoma cells

Hong

Nguyen

et al. 2008

Korean J. Chem. Eng.

View full text Add to dashboard Cite

show abstract

La dermatología española fuera de españa, 2000

2002

Actas Dermo-Sifiliográficas

View full text Add to dashboard Cite

Pharmaceutical industry sponsorship of academic conferences: ethics of conflict of interest

Jayasinghe

2020

J Med Ethics

View full text Add to dashboard Cite

Sponsorship of medical conferences by the pharmaceutical industry has led to many ethical issues, especially in resource-poor developing countries. The core issue in these instances is to reduce or avoid conflicts of interests (COIs). COI is a set of circumstances that creates a risk that professional judgment or actions regarding a primary interest will be unduly influenced by secondary interests. Disruption of social trust should also be considered. This deontological approach should be complemented by a consequentialist approach. Towards this, the concept of distal interests (DI) is introduced. DI lies beyond the immediately visible COIs and the consequences of immediate decisions. They are ‘distal’ in time or place: ‘DI in time’ means consequence of the decision in future scenarios, while ‘DI in space’ means those that impinge on other institutions or bodies. In judging the consequences, it is also necessary to consider the reality of the existing relationship between the pharmaceutical industry and organisers of conferences. In more developed countries, these relationships are governed by stricter regulations, adherence to codes of conduct by both parties and stronger institutional oversights. In contrast, developing countries such as Sri Lanka the regulatory environment is lax and the demarcation of interests between the pharmaceutical industry and the medical profession is considerably blurred. Therefore, establishing clear rules of engagement between the stakeholders should be considered as an attempt to clear the muddy waters. The paper proposes a set of guidelines to capture these approaches.

show abstract

The Propriety of Sponsorship of Dermatologic Conferences

Cited by 3 publications

References 1 publication

Inhibition of melanogenesis by Erigeron canadensis via down-regulating melanogenic enzymes in B16F10 melanoma cells

Inhibition of melanogenesis by Erigeron canadensis via down-regulating melanogenic enzymes in B16F10 melanoma cells

La dermatología española fuera de españa, 2000

Pharmaceutical industry sponsorship of academic conferences: ethics of conflict of interest

Contact Info

Product

Resources

About